Publications by authors named "Arumi D"
We assessed the effectiveness and safety of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) using artificial intelligence techniques. This is a retrospective study in 15 Spanish hospitals (2014-2020), including adult AF patients with no history of anticoagulation, thrombosis events, rheumatic mitral valvular heart disease, mitral valve stenosis, or pregnancy. We employed EHRead technology based on natural language processing (NLP) and machine learning (ML), along with SNOMED-CT terminology, to extract clinical data from electronic health records (EHRs).
View Article and Find Full Text PDFArticle Synopsis
- A predictive model was created to estimate the risk of major bleeding in cancer patients undergoing anticoagulant treatment for venous thromboembolism (VTE) within six months following their diagnosis.
- The study analyzed data from electronic health records across nine hospitals in Spain, using natural language processing and machine learning to identify key predictors of bleeding and develop various predictive algorithms.
- Findings indicated that about 10.9% of the patients experienced major bleeding events after VTE diagnosis, with significant predictors being factors like hemoglobin levels and age, and the new models outperformed the existing CAT-BLEED score.
Introduction: Oral anticoagulation (OAC) is key in atrial fibrillation (AF) thromboprophylaxis, but Spain lacks substantial real-world evidence. We aimed to analyze the prevalence, clinical characteristics, and treatment patterns among patients with AF undertaking OAC, using natural language processing (NLP) and machine learning (ML).
Materials And Methods: This retrospective study included AF patients on OAC from 15 Spanish hospitals (2014-2020).
Objective: To analyse the characteristics and use of digital health tools (DHT) in inflammatory bowel disease (IBD).
Methods: We performed a qualitative study based on a narrative literature review, a questionnaire and on the opinion of 3 expert gastroenterologists. Several searches were carried out until September 2022 through Medline to identify articles on the use of DHT in IBD by healthcare professionals.
Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by itchy, painful, and dry skin. Despite the great number of available therapies, economic evaluations are still needed to provide evidence on their cost efficiency. This research aimed to evaluate the cost effectiveness of the Janus kinase (JAK) inhibitor abrocitinib (200 mg) compared with dupilumab (300 mg), tralokinumab (300 mg), baricitinib (2 and 4 mg), and upadacitinib (15 and 30 mg) for the treatment of patients with severe AD from the Spanish National Health System (NHS) perspective.
View Article and Find Full Text PDFObjective: Evaluate the safety profile and tolerability of topical phosphodiesterase 4 (PDE4) inhibitors versus vehicle as treatment for atopic dermatitis in published studies.
Methods: A search was performed in Medline/PubMed, Web of Science, and Cochrane Library databases on September 27, 2021, by 1 evaluator, without restrictions on publication dates or languages. Terms such as , and were included.
Aim: Recent studies have compared the efficacy and safety of direct-acting oral anticoagulants (DOAC) and low-molecular-weight heparin (LMWH) for cancer-associated venous thromboembolism (VTE). However, there is no available cost-effectiveness analysis comparing DOAC and LMWH. The study aimed to conduct a cost-effectiveness analysis of DOAC (apixaban, edoxaban, and rivaroxaban) LMWH for the treatment of cancer-associated VTE in Spain from the Spanish healthcare system perspective.
View Article and Find Full Text PDFIntroduction And Objective: In Spain, vitamin K antagonists (VKA) remain the standard treatment for the prevention of thromboembolic and hemorrhagic complications in patients with atrial fibrillation (AF), despite the high risks of suffering adverse effects. The objective of this study was to characterize the profile of VKA-treated patients suffering from stroke/systemic embolism (SE) or major hemorrhagic episodes, their evolution and the actions taken after those episodes.
Materials And Methods: EVENTHO was an observational multicenter study conducted in 22 Anticoagulation Spanish Units.
Objective: In non-valvular atrial fibrillation (NVAF) patients at risk of stroke, anticoagulant drugs are less likely to be received by older patients than younger patients. In this study, an attempt is made to discover whether the reasons reported by physicians for denying anticoagulant drugs prescription differ between older and younger atrial fibrillation patients.
Materials And Methods: A retrospective, cross-sectional, multicentre study was conducted from October 2014 to July 2015.
Article Synopsis
- The study aimed to identify baseline characteristics that help predict which patients with overactive bladder (OAB) would benefit more from a higher dose of fesoterodine (8 mg) compared to a lower dose (4 mg).
- It was found that factors like younger age, more frequent urination, and longer duration of OAB were significant predictors of patients needing a dose increase, although baseline urgency urinary incontinence (UUI) episodes were not.
- Results showed that patients who escalated to fesoterodine 8 mg had a significant improvement in UUI episodes compared to those at 4 mg and placebo, but higher doses also led to increased side effects like dry mouth and constipation, suggesting starting with 4 mg may
Article Synopsis
- * Among 897 patients, 610 were considered suboptimal responders to tolterodine, but those who switched to fesoterodine showed a better response, with nearly 70% improvement.
- * Key predictors for improved UUI response with fesoterodine included previous drug treatments, lower baseline UUI severity, and prior antimuscarinic use before the study.
Background: overactive bladder (OAB) is a common condition in older persons. Antimuscarinic treatment remains the mainstay of treatment of OAB but clinicians have been reluctant to prescribe this to older patients. This study examined efficacy and safety information from patients >65 in fesoterodine trials to reaffirm efficacy and to explore the relationships between treatment emergent adverse events (TEAEs), coexisting medication and co-morbidity.
View Article and Find Full Text PDFObjective: To describe the profile of the overactive bladder (OAB) patient on treatment with flexible-dose antimuscarinic treatment in daily clinical practice.
Methods: This was an observational, retrospective and multicenter study, carried out at 88 public and private hospitals. Adult patients diagnosed with OAB who initiated flexible-dose antimuscarinic treatment.
Development of a predictive model for urgency urinary incontinence.
Contemp Clin Trials
November 2016
Article Synopsis
- The development of a Physician Predictive Tool aims to help set realistic treatment expectations for patients with overactive bladder (OAB), improving their engagement and adherence.
- This tool is based on predictive modelling using data from eight Phase 3 and 4 clinical trials involving fesoterodine, allowing predictions of individual treatment responses based on baseline characteristics.
- The text outlines the data used, the model development process, and discusses both the potential benefits and limitations of using this predictive tool in clinical practice.
Objective: To explore the impact of urgency urinary incontinence (UUI) on well-being in non-institutionalized patients with overactive bladder (OAB) in a community sample.
Methods: A cross-sectional web-based study was conducted in the general population, including males and females, >18 years of age. Patients with probable OAB were identified using a validated algorithm together with a score ≥8 on the OAB-V8 scale.
Objective: To summarize published evidence on the pharmacology, efficacy, and safety of fesoterodine for the treatment of overactive bladder (OAB) symptoms in relation to patient clinical and demographic profiles.
Methods: A systematic review of published articles on fesoterodine was conducted via a PubMed search. Articles were identified using the search term fesoterodine, with limits of human species and abstract available.
Overactive bladder (OAB) is a common condition, with prevalence rates increasing with advancing age. Symptoms of OAB, including urgency urinary incontinence (UUI), are associated with various co-morbidities in elderly individuals (e.g.
View Article and Find Full Text PDFAims: To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg.
Methods: In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturitions and ≥ 2 to < 15 urgency urinary incontinence (UUI) episodes/24 h, and suboptimal response to tolterodine ER 4 mg (defined as ≤ 50% reduction in UUI episodes during 2-week run-in) were randomised to fesoterodine (4 mg for 1 week, 8 mg for 11 weeks) or placebo once daily.
Aim: To compare the effects of additional educational material on treatment satisfaction of overactive bladder (OAB) patients treated with a muscarinic receptor antagonist.
Methods: In an observational study of OAB patients being treated by their physician with fesoterodine for 4 months (FAKTEN study), sites were randomised to providing standard treatment or additional educational material including the SAGA tool. Patient satisfaction was assessed by three validated patient-reported outcomes including the Treatment Satisfaction Question.
Aims: To systematically review dose-escalation data from flexible-dose studies of fesoterodine and summarise factors associated with dose-escalation decisions.
Methods: A PubMed search was conducted using the terms (fesoterodine AND flexible dose), with no limits. Articles were included if they contained fesoterodine dose-escalation data for efficacy or safety outcomes or factors associated with dose-escalation decisions.
Background And Objective: To perform the psychometric validation in the Spanish population of the Overactive Bladder Awareness Tool (OAB-V8) scale and its abbreviated version OAB-V3 for screening patients with probable overactive bladder (OAB).
Patients And Methods: A cross-sectional study was conducted in a population aged over 18 years, which was representative of the prevalence of OAB in Spain using an online methodology (Internet survey). Psychometric properties included feasibility, reliability, and validity.
Article Synopsis
- The study aims to explore factors influencing the dose escalation of antimuscarinics for overactive bladder in older patients and its effect on treatment effectiveness.
- A post hoc analysis from the SOFIA study examines patients aged 65 and above who either increased their fesoterodine dosage or did not, assessing predictors and outcomes at weeks 4 and 12.
- Key findings indicate that certain baseline variables like body mass index and male gender, as well as changes in urgency episodes and patient perception of bladder control, were linked to the decision to escalate dosage, though escalators experienced slightly reduced treatment outcomes by the end of the study.
Objective: To explore the relationship between the severity of urinary urge incontinence (UUI) on healthcare resources utilization (HRU) and loss of labor productivity of subjects with overactive bladder (OAB) in the general population in Spain.
Methods: Secondary analysis of a cross-sectional web-based study conducted in the general population >18 years, through a battery of HRU questions asked using an online method. Probable OAB subjects were identified using a previously validated algorithm and a score >8 in the OAB-V8 questionnaire.
Objectives: To explore in the daily clinical practice setting that antimuscarinic, Fesoterodine or Solifenacin, provides a greater clinical benefit after changing their prior Overactive Bladder (OAB) therapy with tolterodine extended-release (ER) to other novel antimuscarinic agents.
Material And Methods: A post-hoc analysis of data from an observational multicenter, cross-sectional, retrospective study. Adult patients of both sexes, with OAB and OAB-V8 score≥8, who switched to fesoterodine or solifenacin within the 3-4 months before study visit from their prior tolterodine-ER-based therapy due to poor response were included.